A Reliable Research Partner in Life Science and Medicine

Recombinant Human BRD4 (N-10His-Flag)

Catalog Number: PKSH033982

Note: Centrifuge before opening to ensure complete recovery of vial contents.

		crip					
	00	CI	411	n	П	n	m
JU	\mathbf{c}	U		J A	ш	v.	ш

Species Human

Source E.coli-derived Human BRD4 protein Glu49-Glu460, with an N-terminal His & Flag

 Mol_Mass
 49.0 kDa

 Accession
 060885

Bio-activity Not validated for activity

Properties

Purity > 90 % as determined by reducing SDS-PAGE.

Endotoxin $< 1.0 \text{ EU per } \mu\text{g}$ of the protein as determined by the LAL method. **Storage** Storage Stor

Shipping This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel


packs. Upon receipt, store it immediately at < - 20°C.

Formulation Supplied as a 0.2 μm filtered solution of 50mM HEPES, 200mM NaCl, 1mM DTT,

10% Glycerol, pH 7.5.

Reconstitution Not Applicable

Data



> 90 % as determined by reducing SDS-PAGE.

Background

Bromodomain-containing protein 4 (BRD4) is a member of the BET class chromatin reader proteins that bind acetylated histones and play a key role in transcriptional regulation and transmission of epigenetic memory. Remains associated with acetylated chromatin throughout the entire cell cycle and provides epigenetic memory for postmitotic Gl gene transcription by preserving acetylated chromatin status and maintaining high-order chromatin structure. BRD bromodomains serve as recognition motifs for acetylated lysine residues on histones, while the NET domain may function by promoting phosphorylation of the C-terminal domain (CTD) of RNA Polymerase II. Some specific inhibitors of BRD4 that prevent binding to acetylated histones by binding Asn-140 and Asn-433 are promising therapeutic molecules for the treatment of leukemias. BRD4 is a potential therapeutic target in many diseases including breast cancer, AML, multiple myeloma, colon cancer and others.

For Research Use Only